In the Canadian Longitudinal Study on Aging cohort, participants with the highest xylitol levels had a 57% higher risk of death, myocardial infarction, or stroke over a six-year follow-up compared to those with the lowest levels. In the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort, participants with the highest xylitol levels had an 18% greater risk of major adverse cardiovascular events over a 30-year period compared to those with the lowest levels.

Both cohorts showed a dose-dependent association where higher blood xylitol concentrations corresponded to higher rates of cardiovascular events. The increased cardiovascular risks persisted after researchers adjusted for factors including age, gender, body mass index, hypertension, diabetes, and lipid levels.

Xylitol is a sugar alcohol commonly used as a low-calorie sweetener and sugar substitute in foods, drinks, chewing gum, and dental care products. Previous research indicated that xylitol can enhance the ability of platelets to form clots, providing a potential biological mechanism for the observed associations.

The study was observational and does not prove that xylitol causes cardiovascular events. High levels of xylitol in the blood do not necessarily reflect dietary consumption, as the sugar alcohol can be produced naturally in the body during glucose metabolism.

Dr. Marco Witkowski, a doctor affiliated with Charité University Hospital in Berlin, Germany, addressed the broader context of sweetener use. "Artificial sweeteners are consumed by people who think they are healthier than sugar, and they are generally regarded as safe by regulatory agencies." Witkowski said.

Witkowski emphasized the need for continued investigation given the prevalence of the additive. "Our long-term findings in the general population highlight how little we know about the cardiovascular safety of xylitol and indicate that further studies are warranted, especially as the amount of xylitol in products continues to increase," he said.

Dr. Aseem Malhotra, a cardiologist and public health campaigner based in London, offered a clinical perspective on artificial sweeteners. "These disturbing findings with [a] plausible mechanism of xylitol increasing cardiovascular risk should be taken very seriously," Malhotra said.

Why It Matters

The study shows a potential conflict between the perceived safety of artificial sweeteners and emerging data on cardiovascular risk. Regulatory agencies generally regard these substances as safe, yet the dose-dependent association found in two large cohorts suggests a need for reevaluation. The events described span 24 years, from 1995 to 2019, covering a significant period of dietary shift toward low-calorie alternatives.

The findings raise questions about whether high blood xylitol levels result from dietary intake or natural metabolic processes. As xylitol is added to thousands of products, often in amounts more than 1,000-fold higher than natural occurrences, understanding its long-term impact becomes critical for public health guidance. The observational nature of the data means causality remains unproven, but the consistency across different populations warrants attention.

What's New

Additional reporting includes historical context from prior publications. Research titled "Abstracts of papers presented at the V Meeting of the Bielschowsky Society for the Study of Strabismus Hamburg, Germany, 18-19 March, 1995" was published in 1995 in Strabismus. A study titled "Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry" was published in 2019 in European Journal of Preventive Cardiology.

A study titled American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy was published in 2003 in Circulation. Professor Dan Atar of the ESC Communication Committee stated that causalities are difficult to infer in observational studies but further studies are mandated into the topic. Background information notes that the European Prospective Investigation is a Europe-wide cohort study of diet and cancer, and a Longitudinal Study is a study with repeated observations over time.

How Sources Differ

Sources differ on specific details regarding the ESC Cardiology presentation. The ESC Cardiology Congress presentation reported that a study presented at the ESC Cardiology Congress in Germany found that higher levels of xylitol in the blood were associated with an increased risk of major adverse cardiovascular events. The European Journal of Preventive Cardiology published a study titled Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry in 2019.

Sources also differ on the specific study titles referenced. The European Journal of Preventive Cardiology featured the EUROASPIRE V registry study in 2019. Meanwhile, doi.org lists a study titled American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy published in 2003 in Circulation.